Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis
NCT06751238Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Sep 2025
- Primary completion
- Oct 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of secukinumab in juvenile psoriatic arthritis (JPsA), sponsored by Novartis. Primary endpoints: Maximum concentration on Day 1, Maximum concentration at steady-state at Day 365 and 3 more. Started Sep 2025; status: recruiting.
02
Drugs
secukinumab
03
Conditions
juvenile psoriatic arthritis (JPsA)
Beyond the preview
Go deeper on NCT06751238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06751238.